Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Institution	Shares	Value	Change
BlackRock	2,941,851	$205M	INCREASED
State Street	909,679	$64M	INCREASED
Emerald Advisers	390,158	$27M	DECREASED
Emerald Mutual Fund Advisers Trust	255,587	$18M	DECREASED
Deutsche Bank AG\	239,831	$17M	INCREASED

Nektar Therapeutics (NKTR) Ownership & Trading Activity

Top Institutional Holders